Multiple Myeloma · Active Clinical Trials
As of 2026-10-21, the full China registry snapshot contains 64 active multiple myeloma interventional trials across 31 provincial-level regions and 316 China study centres, see landscape index. The list below provides peer-reviewed published English translations and can be filtered by modality, target, phase, and province.
Notice for International Patients
These records are provided for research-information purposes. An English summary does not mean that the clinical trial accepts international patients. Eligibility, language requirements, residence requirements and long-term follow-up must be confirmed directly with the clinical trial team. Original registry filings remain in Chinese. For a non-trial route, see independent guide to CAR-T in China.
Trial Decision Guides
All trial FAQsNotice for Patients on Stable Therapy:If your current regimen is effective, do not discontinue standard treatment. Clinical trial matching is recommended upon documented disease progression.
A Phase I Clinical Trial of QLS32015 for Injection Evaluating Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy in Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Shandong Cancer Hospital affiliated to Shandong First Medical University 等 11 家
Target / Modality
GPRC5D × CD3-targeting bispecific antibody